The Latest Journal Articles in Urology

1Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancerOncoTargets and Therapy, April 24, 2015  Full Text  Clinical Article
2Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferationProstate Cancer & Prostatic Diseases, April 24, 2015  Clinical Article
3Effect on hemostasis of an absorbable hemostatic gelatin sponge after transrectal prostate needle biopsyInternational Braz J Urol, April 24, 2015  Full Text  Clinical Article
4Efficacy of a vaporization-resection of the prostate median lobe enlargement and vaporization of the prostate lateral lobe for benign prostatic hyperplasia using a 120-W GreenLight high-performance system laser: The effect on storage symptomsLasers in Medical Science, April 24, 2015  Clinical Article
5Preoperative erectile function and the pathologic features of prostate cancerInternational Braz J Urol, April 24, 2015  Full Text  Clinical Article
6Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failureThe Oncologist, April 24, 2015  Full Text  Clinical Article
7Advances in imaging modalities in prostate cancerCurrent Opinion in Oncology, April 24, 2015  Review Article
8Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 studyEuropean Journal of Cancer, April 24, 2015  Clinical Article
9Implications of ubiquitin ligases in castration-resistant prostate cancerCurrent Opinion in Oncology, April 24, 2015  Review Article
10Risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experienceBMC Urology, April 24, 2015  Full Text  Clinical Article
1'Targeted' ovarian cancer drug could also help certain men with prostate cancerCancer Research UK News, April 24, 2015
2Race is variable in obesity's risk for prostate cancerUW Medicine, April 23, 2015
3Trial shows benefit of 'BRCA-targeting' drug in prostate cancerInstitute of Cancer Research, April 23, 2015
4Prostate cancer treatment in New Hampshire evolves with new understanding, technologyNorris Cotton Cancer Center News, April 22, 2015
5Multiparametric MRI, ultrasound/MRI fusion biopsy detect more clinically, sonographically occult prostate cancersAmerican Roentgen Ray Society News, April 21, 2015
6New treatment for older men with 'slow flow' problemsUNSW Australia Health News, April 20, 2015
7University Hospitals Geauga Medical Center performs first-ever prostate cancer treatment with new deviceUniversity Hospitals Case Medical Center News, April 20, 2015
8Could maple syrup help cut use of antibiotics?McGill University News, April 17, 2015
9Non-invasive device instantly diagnoses urinary tract infectionsThe University of British Columbia Health News, April 16, 2015
10Paternal sperm may hold clues to autismJohns Hopkins Medicine, April 16, 2015

Show Me:

Chromogranin A staining as a biomarker for prostate adenocarcinoma

As reported in The Prostate, chromogranin A (CgA) staining, an indicator of neuroendocrine differentiation, is associated with decreased biochemical control, clinical failure, increased distant metastases, and decreased cause-specific survival in patients with prostate adenocarcinoma and a GS ≥ 7 (n=285). The median follow-up was 6.5 y. CgA staining was present in 31% of specimens. The 10-y distant metastases rate in specimens with <1% and >1% CgA staining was 8% and 48%, respectively. The 10-y cause-specific survival in specimens with <1% and >1% CgA staining was 95% vs. 76%, respectively.

High expression of MUC1 + HER3 is associated with favorable outcome in bladder cancer patients

As reported in BJU International, elevated co-expression of MUC1 + HER3 was associated with improved survival in patients with bladder cancer. MUC1 alone, or elevated MUC1 + non-elevated HER3, had no prognostic value. Moreover, MUC1 was not predictive of survival, tumor stage, or tumor grade.

3-month PSA is a predictor of BCR-free survival after radical prostatectomy

As reported in the International Journal of Clinical Oncology, the 5-year biochemical recurrence (BCR)-free survival rate is significantly higher in patients with a 3-month PSA level < 0.010 ng/ml compared to patients with a 3-month PSA level between 0.010 and 100 ng/ml (92.6% vs. 57.4%). Amongst 174 men who underwent radical prostatectomy for clinically localized prostate cancer, 18.4% had a BCR and the median time to BCR was 16 months.

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocPre-toilet trained infants with febrile UTI have lower voiding efficiency.

Clinical Pearl from Smartest DocPTEN loss at the time of prostate biopsy predicts time to development of metastasis.

Clinical Pearl from Smartest DocQuantification of proteinuria in kidney transplant recipients is important for diagnostic and prognostic purposes.

New! Conference Interviews

Video Interview

Conference reports and videos; experts discuss new research! See the Latest Highlights